| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Influenza, Human | 9 | 2023 | 925 | 1.140 |
Why?
|
| Respiratory Insufficiency | 5 | 2023 | 330 | 0.970 |
Why?
|
| Extracorporeal Membrane Oxygenation | 7 | 2023 | 581 | 0.810 |
Why?
|
| Apnea | 1 | 2020 | 30 | 0.750 |
Why?
|
| Brain Death | 1 | 2020 | 53 | 0.730 |
Why?
|
| Systemic Inflammatory Response Syndrome | 7 | 2023 | 182 | 0.730 |
Why?
|
| Advance Care Planning | 1 | 2021 | 86 | 0.730 |
Why?
|
| GABA Modulators | 1 | 2018 | 15 | 0.670 |
Why?
|
| Pentobarbital | 1 | 2018 | 29 | 0.670 |
Why?
|
| Child | 47 | 2023 | 29154 | 0.620 |
Why?
|
| Status Epilepticus | 1 | 2018 | 145 | 0.580 |
Why?
|
| Terminal Care | 1 | 2021 | 447 | 0.550 |
Why?
|
| Drug Resistant Epilepsy | 1 | 2018 | 181 | 0.540 |
Why?
|
| Coinfection | 2 | 2019 | 189 | 0.530 |
Why?
|
| Water-Electrolyte Imbalance | 2 | 2017 | 92 | 0.520 |
Why?
|
| Intensive Care Units, Pediatric | 8 | 2021 | 441 | 0.480 |
Why?
|
| Acute Kidney Injury | 6 | 2021 | 739 | 0.480 |
Why?
|
| Respiratory Tract Infections | 3 | 2023 | 437 | 0.470 |
Why?
|
| Influenza A Virus, H1N1 Subtype | 2 | 2012 | 242 | 0.460 |
Why?
|
| Nervous System Diseases | 3 | 2023 | 500 | 0.460 |
Why?
|
| Child, Hospitalized | 3 | 2022 | 62 | 0.420 |
Why?
|
| Pediatrics | 1 | 2021 | 1141 | 0.410 |
Why?
|
| Staphylococcal Infections | 2 | 2019 | 672 | 0.410 |
Why?
|
| Critical Illness | 12 | 2022 | 714 | 0.400 |
Why?
|
| Child, Preschool | 24 | 2022 | 16273 | 0.400 |
Why?
|
| Blood Coagulation Disorders | 1 | 2012 | 120 | 0.400 |
Why?
|
| Fluid Therapy | 1 | 2012 | 182 | 0.380 |
Why?
|
| Myelitis | 2 | 2020 | 26 | 0.360 |
Why?
|
| Infant | 21 | 2023 | 13310 | 0.350 |
Why?
|
| Neuromuscular Diseases | 2 | 2020 | 63 | 0.350 |
Why?
|
| Adolescent | 29 | 2023 | 31252 | 0.330 |
Why?
|
| Staphylococcus aureus | 1 | 2012 | 548 | 0.330 |
Why?
|
| Oxygen | 1 | 2012 | 754 | 0.310 |
Why?
|
| Hospital Mortality | 4 | 2022 | 1274 | 0.280 |
Why?
|
| Severity of Illness Index | 5 | 2019 | 4320 | 0.280 |
Why?
|
| Aftercare | 3 | 2022 | 259 | 0.270 |
Why?
|
| von Willebrand Diseases | 2 | 2019 | 61 | 0.260 |
Why?
|
| Critical Care | 4 | 2021 | 770 | 0.260 |
Why?
|
| Hospitalization | 9 | 2023 | 2083 | 0.260 |
Why?
|
| DEAD Box Protein 58 | 2 | 2022 | 14 | 0.240 |
Why?
|
| Humans | 53 | 2023 | 261506 | 0.240 |
Why?
|
| Hemorrhage | 3 | 2019 | 712 | 0.230 |
Why?
|
| Central Nervous System Viral Diseases | 2 | 2020 | 13 | 0.230 |
Why?
|
| Transcription Factor AP-1 | 1 | 2004 | 246 | 0.220 |
Why?
|
| Respiration, Artificial | 5 | 2023 | 577 | 0.220 |
Why?
|
| Airway Obstruction | 1 | 2006 | 261 | 0.220 |
Why?
|
| Guillain-Barre Syndrome | 1 | 2023 | 35 | 0.220 |
Why?
|
| Receptors, Immunologic | 2 | 2022 | 309 | 0.210 |
Why?
|
| Tachycardia, Supraventricular | 1 | 2022 | 84 | 0.200 |
Why?
|
| Escherichia coli Infections | 1 | 2004 | 241 | 0.200 |
Why?
|
| Interferon Type I | 1 | 2022 | 250 | 0.200 |
Why?
|
| Cardiotonic Agents | 2 | 2021 | 151 | 0.200 |
Why?
|
| Hypoxia | 1 | 2004 | 443 | 0.200 |
Why?
|
| Male | 31 | 2023 | 123000 | 0.190 |
Why?
|
| Creatinine | 2 | 2019 | 531 | 0.180 |
Why?
|
| Immunoglobulins, Intravenous | 1 | 2021 | 180 | 0.180 |
Why?
|
| Communicable Diseases | 1 | 2022 | 193 | 0.180 |
Why?
|
| Patient Discharge | 5 | 2022 | 661 | 0.180 |
Why?
|
| Retrospective Studies | 16 | 2023 | 37905 | 0.180 |
Why?
|
| Neurologic Examination | 1 | 2020 | 245 | 0.180 |
Why?
|
| NF-kappa B | 2 | 2022 | 1549 | 0.180 |
Why?
|
| Renal Replacement Therapy | 1 | 2021 | 135 | 0.180 |
Why?
|
| Respiratory Tract Diseases | 1 | 2020 | 111 | 0.180 |
Why?
|
| Mannose-Binding Lectin | 1 | 2019 | 8 | 0.180 |
Why?
|
| Health Information Systems | 1 | 2020 | 34 | 0.180 |
Why?
|
| Enterovirus Infections | 1 | 2020 | 47 | 0.170 |
Why?
|
| Bacterial Infections | 1 | 2023 | 479 | 0.170 |
Why?
|
| Documentation | 1 | 2021 | 207 | 0.170 |
Why?
|
| Respiratory Syncytial Virus Infections | 1 | 2023 | 427 | 0.170 |
Why?
|
| Female | 30 | 2023 | 141928 | 0.170 |
Why?
|
| Kidney Function Tests | 1 | 2019 | 192 | 0.170 |
Why?
|
| Toll-Like Receptor 4 | 1 | 2020 | 203 | 0.160 |
Why?
|
| Patient-Centered Care | 1 | 2021 | 294 | 0.160 |
Why?
|
| Vasoconstrictor Agents | 1 | 2018 | 151 | 0.160 |
Why?
|
| Influenza A virus | 1 | 2019 | 270 | 0.160 |
Why?
|
| Heart Arrest | 1 | 2022 | 358 | 0.160 |
Why?
|
| Sepsis | 2 | 2022 | 652 | 0.150 |
Why?
|
| Glucocorticoids | 1 | 2021 | 629 | 0.150 |
Why?
|
| Ventricular Dysfunction, Left | 1 | 2021 | 435 | 0.150 |
Why?
|
| Prospective Studies | 11 | 2023 | 12873 | 0.150 |
Why?
|
| Informed Consent | 1 | 2020 | 419 | 0.150 |
Why?
|
| Resuscitation Orders | 1 | 2016 | 68 | 0.140 |
Why?
|
| Infant, Extremely Premature | 1 | 2016 | 75 | 0.140 |
Why?
|
| Orthomyxoviridae | 1 | 2016 | 94 | 0.140 |
Why?
|
| Methicillin-Resistant Staphylococcus aureus | 1 | 2019 | 308 | 0.140 |
Why?
|
| Survivors | 1 | 2021 | 1031 | 0.130 |
Why?
|
| Treatment Outcome | 10 | 2022 | 32848 | 0.130 |
Why?
|
| Stroke | 1 | 2023 | 1144 | 0.120 |
Why?
|
| Quality Improvement | 1 | 2021 | 851 | 0.120 |
Why?
|
| Intensive Care Units | 3 | 2023 | 717 | 0.120 |
Why?
|
| Logistic Models | 3 | 2021 | 3441 | 0.120 |
Why?
|
| Mutation, Missense | 1 | 2019 | 1152 | 0.120 |
Why?
|
| Molecular Diagnostic Techniques | 1 | 2016 | 332 | 0.120 |
Why?
|
| Parents | 1 | 2020 | 998 | 0.120 |
Why?
|
| Length of Stay | 3 | 2018 | 1900 | 0.110 |
Why?
|
| Electronic Health Records | 1 | 2021 | 929 | 0.110 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 2 | 2022 | 6550 | 0.110 |
Why?
|
| Clinical Decision-Making | 1 | 2016 | 524 | 0.110 |
Why?
|
| Pandemics | 3 | 2023 | 1559 | 0.110 |
Why?
|
| Registries | 1 | 2020 | 2170 | 0.110 |
Why?
|
| Follow-Up Studies | 4 | 2020 | 14889 | 0.110 |
Why?
|
| Virus Diseases | 1 | 2016 | 398 | 0.110 |
Why?
|
| Infant, Newborn | 7 | 2022 | 8223 | 0.100 |
Why?
|
| Medical Audit | 1 | 2012 | 188 | 0.100 |
Why?
|
| Acute Disease | 3 | 2020 | 2422 | 0.100 |
Why?
|
| Decision Support Techniques | 1 | 2017 | 622 | 0.100 |
Why?
|
| Factor V | 1 | 2011 | 20 | 0.100 |
Why?
|
| United States | 7 | 2023 | 15433 | 0.100 |
Why?
|
| Cross-Sectional Studies | 4 | 2023 | 4314 | 0.100 |
Why?
|
| Oximetry | 1 | 2012 | 172 | 0.100 |
Why?
|
| Emergency Service, Hospital | 1 | 2018 | 1148 | 0.090 |
Why?
|
| Quality of Life | 2 | 2021 | 4532 | 0.090 |
Why?
|
| Proportional Hazards Models | 2 | 2022 | 4988 | 0.090 |
Why?
|
| Linear Models | 1 | 2012 | 1085 | 0.080 |
Why?
|
| Multivariate Analysis | 2 | 2017 | 4298 | 0.080 |
Why?
|
| Decision Making | 1 | 2016 | 1287 | 0.080 |
Why?
|
| Biomarkers | 5 | 2022 | 5047 | 0.080 |
Why?
|
| Signal Transduction | 2 | 2020 | 11965 | 0.080 |
Why?
|
| Interleukin-18 | 1 | 2007 | 100 | 0.070 |
Why?
|
| Lipocalins | 1 | 2007 | 54 | 0.070 |
Why?
|
| Acute-Phase Proteins | 1 | 2007 | 79 | 0.070 |
Why?
|
| Nurses | 1 | 2007 | 80 | 0.070 |
Why?
|
| Peritonsillar Abscess | 1 | 2006 | 4 | 0.070 |
Why?
|
| Retropharyngeal Abscess | 1 | 2006 | 11 | 0.070 |
Why?
|
| Epiglottitis | 1 | 2006 | 16 | 0.070 |
Why?
|
| Tracheitis | 1 | 2006 | 21 | 0.070 |
Why?
|
| Croup | 1 | 2006 | 15 | 0.070 |
Why?
|
| Workload | 1 | 2007 | 198 | 0.070 |
Why?
|
| Laryngeal Diseases | 1 | 2006 | 49 | 0.070 |
Why?
|
| Risk Factors | 5 | 2023 | 17523 | 0.070 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2019 | 5539 | 0.070 |
Why?
|
| Hospitals, Pediatric | 2 | 2022 | 773 | 0.070 |
Why?
|
| Odds Ratio | 2 | 2022 | 2316 | 0.060 |
Why?
|
| Medical Errors | 1 | 2007 | 219 | 0.060 |
Why?
|
| Glutathione Disulfide | 1 | 2004 | 20 | 0.060 |
Why?
|
| Thrombosis | 1 | 2011 | 781 | 0.060 |
Why?
|
| Xanthine Oxidase | 1 | 2004 | 19 | 0.060 |
Why?
|
| NF-KappaB Inhibitor alpha | 1 | 2004 | 136 | 0.060 |
Why?
|
| Young Adult | 5 | 2022 | 21445 | 0.060 |
Why?
|
| Brain Infarction | 1 | 2004 | 31 | 0.060 |
Why?
|
| Marijuana Smoking | 1 | 2004 | 39 | 0.060 |
Why?
|
| Steroids | 1 | 2006 | 356 | 0.060 |
Why?
|
| I-kappa B Proteins | 1 | 2004 | 170 | 0.060 |
Why?
|
| Crowding | 1 | 2023 | 8 | 0.060 |
Why?
|
| NF-kappa B p52 Subunit | 1 | 2022 | 26 | 0.060 |
Why?
|
| Intubation, Intratracheal | 1 | 2007 | 445 | 0.050 |
Why?
|
| Respiratory Syncytial Viruses | 1 | 2023 | 171 | 0.050 |
Why?
|
| Family Characteristics | 1 | 2023 | 102 | 0.050 |
Why?
|
| Oxidation-Reduction | 1 | 2004 | 717 | 0.050 |
Why?
|
| Multiple Organ Failure | 1 | 2023 | 177 | 0.050 |
Why?
|
| Glutathione | 1 | 2004 | 368 | 0.050 |
Why?
|
| Cytoplasm | 1 | 2004 | 652 | 0.050 |
Why?
|
| Case-Control Studies | 2 | 2023 | 6100 | 0.050 |
Why?
|
| Glasgow Coma Scale | 1 | 2022 | 215 | 0.050 |
Why?
|
| Immunoassay | 1 | 2022 | 216 | 0.050 |
Why?
|
| Neutralization Tests | 1 | 2022 | 299 | 0.050 |
Why?
|
| Seasons | 1 | 2023 | 340 | 0.050 |
Why?
|
| Public Health Surveillance | 1 | 2021 | 63 | 0.050 |
Why?
|
| Interferons | 1 | 2022 | 291 | 0.050 |
Why?
|
| Haploinsufficiency | 1 | 2022 | 294 | 0.050 |
Why?
|
| Laboratories, Hospital | 1 | 2021 | 29 | 0.050 |
Why?
|
| Patient Acuity | 1 | 2021 | 72 | 0.050 |
Why?
|
| Viral Envelope Proteins | 1 | 2022 | 207 | 0.050 |
Why?
|
| Antigens, Viral | 1 | 2022 | 471 | 0.050 |
Why?
|
| Age Factors | 2 | 2021 | 5377 | 0.050 |
Why?
|
| Cohort Studies | 3 | 2021 | 9244 | 0.050 |
Why?
|
| Cerebellum | 1 | 2004 | 449 | 0.050 |
Why?
|
| Shock | 1 | 2021 | 88 | 0.050 |
Why?
|
| Coagulants | 1 | 2019 | 8 | 0.050 |
Why?
|
| Spike Glycoprotein, Coronavirus | 1 | 2022 | 222 | 0.050 |
Why?
|
| Obesity | 2 | 2023 | 2884 | 0.050 |
Why?
|
| Morbidity | 1 | 2021 | 397 | 0.050 |
Why?
|
| Risk Assessment | 1 | 2012 | 6869 | 0.050 |
Why?
|
| Infectious Disease Transmission, Vertical | 1 | 2022 | 234 | 0.040 |
Why?
|
| Leukocytes, Mononuclear | 1 | 2022 | 709 | 0.040 |
Why?
|
| Immunomodulation | 1 | 2021 | 242 | 0.040 |
Why?
|
| Factor VIII | 1 | 2019 | 75 | 0.040 |
Why?
|
| Patient Admission | 1 | 2021 | 220 | 0.040 |
Why?
|
| Rats, Sprague-Dawley | 1 | 2004 | 2063 | 0.040 |
Why?
|
| Incidence | 2 | 2021 | 5673 | 0.040 |
Why?
|
| Delphi Technique | 1 | 2019 | 210 | 0.040 |
Why?
|
| Reactive Oxygen Species | 1 | 2004 | 987 | 0.040 |
Why?
|
| Autoantibodies | 1 | 2022 | 576 | 0.040 |
Why?
|
| Medical Staff, Hospital | 1 | 2019 | 118 | 0.040 |
Why?
|
| Combined Modality Therapy | 2 | 2021 | 8865 | 0.040 |
Why?
|
| Texas | 2 | 2020 | 6311 | 0.040 |
Why?
|
| Arrhythmias, Cardiac | 1 | 2022 | 473 | 0.040 |
Why?
|
| Adult | 6 | 2023 | 77950 | 0.040 |
Why?
|
| Cell Nucleus | 1 | 2004 | 1620 | 0.040 |
Why?
|
| Stroke Volume | 1 | 2021 | 577 | 0.040 |
Why?
|
| Early Diagnosis | 1 | 2019 | 298 | 0.040 |
Why?
|
| Propensity Score | 1 | 2021 | 750 | 0.040 |
Why?
|
| Oxidative Stress | 1 | 2004 | 1129 | 0.040 |
Why?
|
| Proto-Oncogene Proteins | 1 | 2007 | 2488 | 0.040 |
Why?
|
| Regression Analysis | 1 | 2021 | 1546 | 0.040 |
Why?
|
| Pregnancy Complications, Infectious | 1 | 2022 | 419 | 0.040 |
Why?
|
| Reference Values | 1 | 2019 | 1099 | 0.040 |
Why?
|
| Inpatients | 1 | 2023 | 678 | 0.040 |
Why?
|
| Membrane Glycoproteins | 1 | 2022 | 1073 | 0.040 |
Why?
|
| Amino Acid Substitution | 1 | 2019 | 644 | 0.040 |
Why?
|
| Neonatologists | 1 | 2016 | 16 | 0.040 |
Why?
|
| Activities of Daily Living | 1 | 2020 | 552 | 0.040 |
Why?
|
| Time Factors | 2 | 2021 | 12926 | 0.040 |
Why?
|
| Multiplex Polymerase Chain Reaction | 1 | 2016 | 49 | 0.040 |
Why?
|
| Syndrome | 1 | 2019 | 1351 | 0.030 |
Why?
|
| Predictive Value of Tests | 2 | 2019 | 4892 | 0.030 |
Why?
|
| Fatal Outcome | 2 | 2011 | 829 | 0.030 |
Why?
|
| Community-Acquired Infections | 1 | 2018 | 285 | 0.030 |
Why?
|
| Transcription, Genetic | 1 | 2004 | 3154 | 0.030 |
Why?
|
| Nasopharynx | 1 | 2016 | 119 | 0.030 |
Why?
|
| Interferon-alpha | 1 | 2020 | 889 | 0.030 |
Why?
|
| Drug Therapy, Combination | 1 | 2021 | 2315 | 0.030 |
Why?
|
| Antibodies, Viral | 1 | 2022 | 1320 | 0.030 |
Why?
|
| Risk | 1 | 2020 | 1972 | 0.030 |
Why?
|
| ROC Curve | 1 | 2018 | 1183 | 0.030 |
Why?
|
| Chi-Square Distribution | 1 | 2018 | 1323 | 0.030 |
Why?
|
| Rats | 1 | 2004 | 6086 | 0.030 |
Why?
|
| Cytokines | 1 | 2004 | 2809 | 0.030 |
Why?
|
| Transcriptome | 1 | 2023 | 1859 | 0.030 |
Why?
|
| Intensive Care Units, Neonatal | 1 | 2016 | 273 | 0.030 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2020 | 1538 | 0.030 |
Why?
|
| Physician's Role | 1 | 2016 | 238 | 0.030 |
Why?
|
| Prevalence | 1 | 2022 | 3260 | 0.030 |
Why?
|
| Liver | 1 | 2004 | 2961 | 0.030 |
Why?
|
| Sex Factors | 1 | 2019 | 2139 | 0.030 |
Why?
|
| Specimen Handling | 1 | 2016 | 299 | 0.030 |
Why?
|
| Neoplasms | 1 | 2020 | 15193 | 0.030 |
Why?
|
| Cost of Illness | 1 | 2017 | 498 | 0.030 |
Why?
|
| Anti-Bacterial Agents | 1 | 2006 | 2992 | 0.030 |
Why?
|
| Transplantation Conditioning | 1 | 2022 | 2238 | 0.030 |
Why?
|
| Databases, Factual | 1 | 2020 | 2218 | 0.030 |
Why?
|
| Antiviral Agents | 1 | 2020 | 1230 | 0.030 |
Why?
|
| Real-Time Polymerase Chain Reaction | 1 | 2016 | 1217 | 0.030 |
Why?
|
| Disease Progression | 1 | 2023 | 6682 | 0.030 |
Why?
|
| Phenotype | 1 | 2023 | 6295 | 0.030 |
Why?
|
| Diagnosis, Differential | 1 | 2021 | 4744 | 0.030 |
Why?
|
| Fibrin Fibrinogen Degradation Products | 1 | 2011 | 68 | 0.020 |
Why?
|
| Prognosis | 2 | 2020 | 21713 | 0.020 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2022 | 4549 | 0.020 |
Why?
|
| Hemoglobins | 1 | 2011 | 477 | 0.020 |
Why?
|
| Pregnancy | 1 | 2022 | 7573 | 0.020 |
Why?
|
| Surveys and Questionnaires | 1 | 2020 | 5687 | 0.020 |
Why?
|
| Lipocalin-2 | 1 | 2007 | 65 | 0.020 |
Why?
|
| Nursing Staff, Hospital | 1 | 2007 | 69 | 0.020 |
Why?
|
| Survival Rate | 1 | 2020 | 12221 | 0.020 |
Why?
|
| Blood Platelets | 1 | 2011 | 731 | 0.020 |
Why?
|
| Headache | 1 | 2004 | 163 | 0.010 |
Why?
|
| Animals | 1 | 2004 | 59536 | 0.010 |
Why?
|
| Sensitivity and Specificity | 1 | 2007 | 4971 | 0.010 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2004 | 7551 | 0.000 |
Why?
|